in situ hybridization (ISH) is a technique that enables the localization of specific DNA or RNA sequences within tissue sections and cytology samples using labeled complementary strands. The target gene can be visualized through brightfield or fluorescence microscopy. Compared to IHC,which broadly localizes proteins within tissues,ISH offers superior sensitivity. ISH not only identifies cells positive for a specific DNA or RNA sequence but also quantifies their level of positivity within individual cells. This makes ISH particularly valuable for studies requiring precise gene-level data within a morphological context.
"},{"faq_question":"What methods of probe detection do you offer for ISH?","faq_answer":"We offer all methods of probe detection to uncover the morphological data of your samples. Our ISH services include fluorescence in situ hybridization (FISH),silver-enhanced in situ hybridization (SISH),and chromogenic in situ hybridization (CISH). For studies requiring a more comprehensive view,we also offer multiplex assays that combine ISH with immunohistochemistry (IHC) on the same slide,enabling simultaneous gene and protein expression analysis in situ.
"},{"faq_question":"What platforms do you use for ISH assays?","faq_answer":"CellCarta has assembled a chain of semi-automated equipment to optimize and standardize ISH processing. FISH assays are performed using the Abbott VP2000 with hybridization steps completed on calibrated ThermoBrite heating modules. SISH assays are run on the Benchmark XT and Ultra automated systems. Multiplex CISH with IHC is performed on the Leica Bond autostainer. FISH signal evaluation and quantification is conducted using Zeiss Axioplan microscopes paired with the BioView imaging system. Chromogenic ISH slides are captured using whole slide digital imaging. All equipment is extensively qualified and undergoes regular quality checks.
"},{"faq_question":"At what stage of development can ISH services be employed?","faq_answer":"CellCarta’s ISH services can be implemented at any stage of therapeutic development,from exploratory studies through to late-phase clinical trials and companion diagnostic (CDx) development. Our platforms are designed to scale with your program:the semi-automated FISH process can handle up to 50 slides per run,while the automated SISH system accommodates up to 30 slides per run. We have successfully deployed cytogenetic FISH assays for the diagnosis,prognosis,and therapeutic surveillance of cancer patients in the clinical setting.
"},{"faq_question":"Can ISH be used to evaluate mRNA expression?","faq_answer":"Yes. CellCarta has extensively evaluated RNAscope (ACD) nucleic acid in situ hybridization technology for mRNA detection in FFPE tissue. RNAscope is validated for use on FFPE cell preparations and can be requested for any target of interest. As each specimen type presents unique challenges,the technology will undergo custom validation to fine-tune the procedure to your specific samples. Client specimens are tested during an assay optimization phase,and results determine whether further validation steps are required.
"}]}#-supreme-cellcarta-service-blocks-7-688{blocks-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/06/IF-and-IHC-Services-73.jpg","image_alt":"IHC services at CellCarta","title":"IHC Services","description":"Insights into the abundance,distribution,and localization of your antigen of interest.","button_text":"Discover","button_url":"/capabilities/histopathology/if-ihc","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/08/CellCarta-616-scaled.jpg","image_alt":"Digital pathology services at CellCarta","title":"Digital Pathology","description":"Cutting-edge digital and AI-powered pathology services to advance your clinical trials.","button_text":"Discover","button_url":"/capabilities/histopathology/digital-pathology/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Genomics-Services-449.jpg","image_alt":"Genomics services at CellCarta","title":"Genomics Services","description":"Genomics solutions for all phases of drug development and CDx development.","button_text":"Discover","button_url":"/capabilities/genomics","button_target":"_self"}]}#-supreme-cellcarta-tab-content-4-688{oxy-supreme-cellcarta-tab-content-content-heading-tag:h3;oxy-supreme-cellcarta-tab-content-content-heading-size:default;oxy-supreme-cellcarta-tab-content-content-body-size:default;tabs-data:[{"tab_title":"Automated Platforms","content_title":"","content_body":"ISH technology provides detailed insight into gene expression within its tissue context,but their standard methodologies are a labor-intensive process.
\nAt CellCarta,we’ve implemented automated platforms to optimize ISH workflows and increase reproducibility.
\nCellCarta has expertise in multiple key ISH platforms,including:
\nAll equipment is qualified and cross-validated by all our global labs to ensure consistent quality and reproducibility.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Cta-banner-CellCarta-455.jpg","image_alt":"ISH assay technology platforms at CellCarta"},{"tab_title":"Clinical Deployment","content_title":"","content_body":"For any clinical trial phase and IVD/CDx development,CellCarta can develop and validate custom ISH assays.
\nCytogenetic FISH assays have been deployed for diagnosis,prognosis,and therapeutic . Our semi-automated FISH process can handle up to 50 slides in one run.
\nSISH assays are performed on the automated Ventana Benchmark XT and Ultra systems,which can handle up to 30 slides in one run.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta-645-scaled.jpg","image_alt":"Clinical ISH assay deployment at CellCarta"}]}